NVNO vs. SEPA, MGRM, SRTS, PDEX, HSAQ, STIM, ICCM, AMIX, LUCD, and CTSO
Should you be buying enVVeno Medical stock or one of its competitors? The main competitors of enVVeno Medical include SEP Acquisition (SEPA), Monogram Orthopaedics (MGRM), Sensus Healthcare (SRTS), Pro-Dex (PDEX), Health Sciences Acquisitions Co. 2 (HSAQ), Neuronetics (STIM), IceCure Medical (ICCM), Autonomix Medical (AMIX), Lucid Diagnostics (LUCD), and Cytosorbents (CTSO). These companies are all part of the "surgical & medical instruments" industry.
enVVeno Medical (NASDAQ:NVNO) and SEP Acquisition (NASDAQ:SEPA) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, risk, dividends, institutional ownership, community ranking, analyst recommendations, profitability, earnings and media sentiment.
34.7% of enVVeno Medical shares are held by institutional investors. Comparatively, 3.7% of SEP Acquisition shares are held by institutional investors. 17.0% of enVVeno Medical shares are held by company insiders. Comparatively, 20.0% of SEP Acquisition shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
In the previous week, enVVeno Medical had 1 more articles in the media than SEP Acquisition. MarketBeat recorded 4 mentions for enVVeno Medical and 3 mentions for SEP Acquisition. enVVeno Medical's average media sentiment score of 1.24 beat SEP Acquisition's score of 0.94 indicating that enVVeno Medical is being referred to more favorably in the media.
enVVeno Medical has a beta of 1.1, suggesting that its share price is 10% more volatile than the S&P 500. Comparatively, SEP Acquisition has a beta of 0.16, suggesting that its share price is 84% less volatile than the S&P 500.
SEP Acquisition's return on equity of 0.00% beat enVVeno Medical's return on equity.
enVVeno Medical received 156 more outperform votes than SEP Acquisition when rated by MarketBeat users.
Summary
enVVeno Medical beats SEP Acquisition on 5 of the 9 factors compared between the two stocks.
Get enVVeno Medical News Delivered to You Automatically
Sign up to receive the latest news and ratings for NVNO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding NVNO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
enVVeno Medical Competitors List
Related Companies and Tools
